



Comparative efficacies of 13 surgical interventions for primary congenital glaucoma in children: a network meta-analysis of randomized clinical trials

Yun Jeong Lee, MD^{a,b}, Ahnul Ha, MD^{e,f,*}, Donghwee Kang^b, Sung Ryul Shim, MPH, PhD^g, Jin Wook Jeoung, MD, PhD^{a,b}, Ki Ho Park, MD, PhD^{a,b}, Young Kook Kim, MD, PhD^{a,b,c,d,*}

Background: Timely and proper intraocular pressure (IOP) management is vital to the prevention of visual impairment in children with primary congenital glaucoma (PCG). Although various surgical interventions have been proposed, no well-founded evidence exists on their comparative efficacies. We aimed to compare the efficacies of surgical interventions for PCG.

Methods: We searched relevant sources up to 4 April 2022. Randomized controlled trials (RCTs) entailing surgical interventions for PCG in children were identified. A network meta-analysis (NMA) was performed, comparing 13 surgical interventions: Conventional partial trabeculectomy ([CPT] control), 240-degree trabeculectomy, Illuminated microcatheter-assisted circumferential trabeculectomy (IMCT), Visco canalostomy, Visco-circumferential-suture-trabeculectomy, Goniotomy, Laser goniotomy, Kahook dual blade *ab-interno* trabeculectomy, Trabeculectomy with mitomycin C, Trabeculectomy with modified scleral bed, Deep sclerectomy, Combined trabeculectomy-trabeculectomy with mitomycin C, and Baerveldt implant. The main outcomes were mean IOP reduction and surgical success rate at postoperative 6 months. The mean differences (MDs) or odds ratios (ORs) were analyzed by a random-effects model, and the efficacies were ranked by *P*-score. We appraised the RCTs using the Cochrane risk-of-bias (ROB) tool (PROSPERO: CRD42022313954).

Results: Sixteen RCTs were eligible for NMA, including 710 eyes of 485 participants and 13 surgical interventions, which formed a network of 14 nodes comprising both single interventions and intervention combinations. IMCT was superior to CPT in both IOP reduction [MD (95% CI): -3.10 (-5.50 to -0.69)] and surgical success rate [OR (95% CI): 4.38 (1.61–11.96)]. The MD and OR comparing the other surgical interventions and intervention combinations with CPT were not statistically significant. The *P*-scores ranked IMCT as the most efficacious surgical intervention in terms of success rate (*P*-score = 0.777). Overall, the trials had a low-to-moderate ROB.

Conclusion: This NMA indicated that IMCT is more effective than CPT and might be the most efficacious of the 13 surgical interventions for management of PCG.

Keywords: primary congenital glaucoma, surgical intervention, efficacy, randomized clinical trial, network meta-analysis

Introduction

Primary congenital glaucoma (PCG) is an optic neuropathy with high intraocular pressure (IOP) characterized by anomalous

development of the anterior chamber angle^[1]. PCG accounts for up to 18% of all cases of childhood blindness^[2–6]. This disease's blinding and progressive nature^[7] necessitates management that is both timely and proper.

^aDepartment of Ophthalmology, Seoul National University Hospital, ^bDepartment of Ophthalmology, Seoul National University College of Medicine, ^cDepartment of Pediatric Ophthalmology, Seoul National University Children's Hospital, ^dEyeLight Data Science Laboratory, Seoul, ^eDepartment of Ophthalmology, Jeju National University Hospital, ^fDepartment of Ophthalmology, Jeju National University College of Medicine, Jeju-si and ^gDepartment of Health and Medical Informatics, Kyungnam University College of Health Sciences, Changwon, Korea

Ahnul Ha and Young Kook Kim contributed equally to this study as co-corresponding authors.

Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.

*Corresponding author. Address: Department of Ophthalmology, Seoul National University Hospital, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul 03080, Republic of Korea. Tel.: +82-2-2072-4301; fax: +82-2-741-3187. E-mail address: md092@naver.com; eyedry@snu.ac.kr (Y. K. Kim); Department of Ophthalmology, Jeju National University Hospital, Jeju National University College of Medicine, 15 Aran 13-gil, Jeju-si, Jeju-do 63241, Republic of Korea. Tel.: +82-64-717-2064; fax: +82-64-717-8276. E-mail address: zzammy486@gmail.com; zzammy486@snu.ac.kr (A. Ha).

Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

International Journal of Surgery (2023) 109:953–962

Received 7 November 2022; Accepted 7 February 2023

Supplemental Digital Content is available for this article. Direct URL citations are provided in the HTML and PDF versions of this article on the journal's website, www.journal-surgery.net.

Published online 31 March 2023

<http://dx.doi.org/10.1097/JS9.000000000000283>

The definitive PCG management approach is surgery, mostly because, for pediatric patients, treatment with medication is poorly tolerated over the long term and less effective than for adults^[1,8]. As PCG's principal pathology is in the anterior chamber angle, two procedures are generally used: goniotomy or trabeculotomy. Both of these address the issue of an angle anomaly and increase aqueous outflow by directly connecting Schlemm's canal to the anterior chamber^[8]. Other types of surgical interventions, such as filtering surgery, glaucoma drainage devices, and cyclodestructive procedures, have also been proposed^[8], with the result that there is considerable heterogeneity in PCG management, even among experts.

Various randomized controlled trials (RCTs) therefore have been done to compare surgical interventions' efficacies for PCG in pediatric patients^[9–24]. Determining their comparative efficacies remains difficult, however, due specifically to the lack of head-to-head comparisons. Moreover, the current accumulated evidence is limited to pairwise comparisons between specific interventions^[25] and lacks comprehensive all-interventions comparisons. Consequently, there is still no well-founded evidence supporting a given intervention's outstanding efficacy for PCG management.

Network meta-analysis (NMA), as an extension of traditional meta-analysis, enables intervention comparison based on not only direct evidence but also indirect evidence (i.e. from interventions that are not directly compared)^[26]. Furthermore, intervention hierarchies can be obtained using valid methods of statistical inference^[27]. Thus motivated, we performed an NMA on RCTs to assess the comparative efficacies of surgical interventions for PCG in pediatric patients.

Methods

The protocol of this systematic review was prospectively registered at PROSPERO (CRD42022313954) https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=313954 and has been published^[28]. This NMA has been reported in accordance with and is fully compliant with the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses), Supplemental Digital Content 1, <http://links.lww.com/JS9/A163>, Supplemental Digital Content 2, <http://links.lww.com/JS9/A164> 2020^[29], and AMSTAR 2, Supplemental Digital Content 3, <http://links.lww.com/JS9/A165> (Assessing the methodological quality of systematic reviews) Guidelines^[30].

Eligibility criteria for present review

RCTs that had compared the efficacies of surgical interventions for PCG in pediatric patients were included. There were no restrictions on any surgical intervention types. Editorials, case reports as well as comments, abstracts, and letters were excluded. Studies that had only compared different application methods (e.g. exposure time and concentration) of the same adjunctive substance such as antimetabolite [e.g. mitomycin C (MMC), 5-fluorouracil] and bevacizumab [e.g. IOP-lowering effect of 'trabeculectomy (TLE) with MMC application for 2 min' vs. 'TLE with MMC application for 4 min'] were also excluded; the reason for the exclusion was that the main purpose of this study was to compare the IOP-lowering effect of the surgical technique itself. In addition, the detailed application methods of adjuncts differed among studies.

HIGHLIGHTS

- The comparative efficacies of surgical interventions for primary congenital glaucoma remain inconclusive.
- Illuminated microcatheter-assisted circumferential trabeculotomy was superior to conventional partial trabeculotomy in both intraocular pressure reduction and success rate.
- Illuminated microcatheter-assisted circumferential trabeculotomy was ranked as the most efficacious intervention in terms of success rate.
- Primary congenital glaucoma-surgical interventions can be ranked by efficacy, and such ranking may be used to facilitate clinical decision making.

Search methods for identification of studies

We systematically searched the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library, PubMed, and EMBASE from inception to 4 April 2022. Our search strategies were developed in collaboration with an academic librarian expert in systematic review, and are based on established terminology such as MESH and EMBASE search terms. The following keywords were included: Congenital, Glaucoma, Surgery, and Children. We also screened the WHO International Clinical Trials Registry Platform, clinicaltrials.gov, and references from published papers to identify additional relevant studies. No language-based restrictions were imposed on our electronic searches. The complete search strategies are available in Supplementary Appendix 1, Supplemental Digital Content 4, <http://links.lww.com/JS9/A166>.

Study selection

To identify pertinent articles, the titles and abstracts of those retrieved were exported to Endnote (version X9; Thomson Reuters), wherein duplicates were removed. The remaining titles and abstracts were assessed by two investigators (D.K./Y.J.L.) independently for eligibility, and for the eligible ones, the relevant full-text articles were retrieved. Then, the same two investigators independently assessed those articles for final eligibility. Eligibility classification discrepancies were resolved through discussion, consensus, or, when needed, third-party (Y.K.K.) adjudication.

Data collection and risk-of-bias assessment

For each of the trials, two individuals (D.K./A.H.) independently extracted data and then entered it (electronic format) into Microsoft Access 2016 (Microsoft Corporation). Any conflicting data entries were identified using an algorithm. The trial characteristics of interest were: (1) study ID (name of first author, year of publication), (2) country of study, (3) length of follow-up, (4) inclusion of participants with history of surgery, (5) surgical interventions, (6) number of eyes (participants), (7) baseline mean age, (8) baseline mean IOP, (9) postoperative 6-month and 1-year mean IOP reduction, and (10) surgical success rate.

Trial quality was evaluated using a revised tool for assessment of risk-of-bias (ROB) in randomized trials (RoB 2)^[27]. The five domains of bias evaluated were as follows: randomization process, adherence to assigned interventions, missing outcome data,

outcome measurement bias, and reported-results bias. Each domain was rated as having a low ROB, ‘some concerns’ or a high ROB. Any domain’s worst ROB was used to determine the overall ROB. In the evaluation, we referred to the Cochrane Database of Systematic Reviews^[25] for previously published articles’ contents that had been confirmed through communication with the authors. ROB was assessed by two investigators (Y.J.L./Y.K.K.) independently, with any discrepancies being resolved via discussion.

Definitions used in categorization of surgical interventions

To improve interpretability and, thereby, support decision making, we grouped the surgical intervention arms into the 13 categories that follow: (1) Conventional partial trabeculotomy ([CPT] control), (2) 240-degree trabeculotomy (240° trabeculotomy), (3) Illuminated microcatheter-assisted circumferential trabeculotomy (IMCT), (4) Viscocanalostomy (VC), (5) Visco-circumferential-suture-trabeculotomy (VCST), (6) Goniotomy, (7) Neodymium-YAG laser goniotomy (laser goniotomy), (8) Kahook dual blade *ab-interno* trabeculectomy (KDB trabeculectomy), (9) Trabeculectomy with mitomycin C (TM), (10) Trabeculectomy with modified scleral bed (TmS), (11) Deep sclerectomy (DS), (12) Combined trabeculectomy-trabeculotomy with mitomycin C (CTTM), and (13) Baerveldt implant (Table 1). Each surgical intervention is described in detail in Supplementary Table 1, Supplemental Digital Content 4, <http://links.lww.com/JS9/A166>.

Outcomes

The primary outcome measure was the amount of mean IOP reduction at 6 months postoperatively; in a large number of RCTs on PCG surgical interventions, the postoperative observation period was 6 months (as indicated in Table 2), and so the standard for a primary outcome was set at 6 months for this study. When comparing interventions A and B, stated IOP values representing intervention A/B difference were compared; a negative mean difference (MD), therefore, indicated the superiority of intervention A (i.e. a lower IOP). Results of intention-to-treat analyses were extracted preferentially. If postoperative 6-month data were not available, we adopted the data that was closest in terms of time point.

The secondary outcome measure was the surgical success rate at 6 months postoperatively, as defined based on each study’s definition (e.g. proportion of eyes showing IOP equal to or less than a given value, without any signs of glaucoma progression or serious visual complications). All of the definitions can be found in Supplementary Table 2, Supplemental Digital Content 4, <http://links.lww.com/JS9/A166>. We applied qualified success rates to the analysis; in cases where such data were not available, we used the complete (absolute) values instead. Also, if no distinction between complete (absolute) and qualified success was provided, we applied the reported surgical success rate.

Data synthesis

We compared the effects of the competing surgical interventions on the primary outcome (i.e. postoperative 6-month mean IOP reduction) according to the MD with 95% CIs. As for the secondary outcome (i.e. postoperative 6-month surgical success rate), the odds ratio (OR) was calculated by dividing intervention group 1’s success proportion by that of intervention group 2. To combine direct evidence with indirect evidence, an NMA was performed with the R software package ‘netmeta’ (version 4.0.4; The R Foundation), which applies a frequentist method based on a graph-theoretical approach according to electrical network theory^[31,32]. The ‘netmeta’ function takes within-study correlation into account by reweighting, using the Laplacian matrix and its pseudoinverse, all of each multiarm study’s comparisons based on back-calculation of variances^[33]. Because the included studies were small in number and heterogeneous, we applied random-effects models^[34].

Data analysis

We ranked the interventions by *P*-score, which is the most frequent analog of the surface under the cumulative ranking curve (SUCRA)^[32]. The *P*-score, as valued between 0 and 1, is the probability that a certain treatment is among the best ones^[27,35].

We assessed the cross-study heterogeneity of effect estimates and the study heterogeneity effects on the pooled effect estimate using *Q* statistics and *I*² statistics, respectively^[36,37]. Inconsistency (i.e. nonagreement of direct with indirect intervention effects)^[38] was evaluated using Separating Indirect from Direct Evidence (SIDE; a.k.a. node-splitting)^[39].

Table 1
Classifications, types, and designated terms of surgical interventions.

Classification	Type	Designated term
Angle surgery	Conventional partial trabeculotomy	CPT
	204-degree trabeculotomy	240° trabeculotomy
	Illuminated microcatheter-assisted circumferential trabeculotomy	IMCT
	Viscocanalostomy	VC
	Visco-circumferential-suture-trabeculotomy	VCST
	Goniotomy	Goniotomy
	Neodymium-YAG laser goniotomy	Laser goniotomy
Filtering surgery	Kahook dual blade <i>ab-interno</i> trabeculectomy	KDB trabeculectomy
	Trabeculectomy with mitomycin C	TM
	Trabeculectomy with modified scleral bed	TmS
	Deep sclerectomy	DS
Combined surgery	Combined trabeculectomy-trabeculotomy with mitomycin C	CTTM
Glaucoma drainage device	Baerveldt implant	Baerveldt implant

Table 2

Characteristics of studies included in meta-analysis.

References	Country	Follow-up duration (months)	Inclusion of participants with history of surgery	Surgical interventions (study arm)	Number of eyes (participants) randomized	Baseline mean age (months)	Baseline mean IOP (mmHg)	Postoperative 6-month mean IOP reduction (mmHg)	Postoperative 1-year mean IOP reduction (mmHg)	Surgical success rate (%) ^a
Elwehidy <i>et al.</i> ^[9]	Egypt	36	No	VCST	84 (49)	4.8 (2.1)	29.1 (3.3)	17.9 (3.0)	17.7 (3.0)	94.6
Elhilali <i>et al.</i> ^[10]	Egypt	12	No	CPT + VC	42 (29)	4.9 (1.7)	29.9 (3.2)	18.0 (2.8)	17.1 (2.8)	87.8
				KDB trabeculectomy		9.1 (9.6)	24.4 (6.8)	10.1 (6.0)	12.6 (6.0)	57.1 ^b
Elwehidy <i>et al.</i> ^[11]	Egypt	60	No	Goniotomy	154 (92)	6.3 (3.9)	23.1 (3.7)	9.9 (3.3)	10.3 (3.3)	57.1 ^b
				CPT + VC		5.0 (2.3)	26.5 (2.9)	15.0 (2.5)	14.4 (2.5)	89.7
Bor'i <i>et al.</i> ^[12]	Egypt	14 (13–22) ^c	No	CPT	50 (25)	5.0 (2.9)	27.9 (3.1)	16.2 (2.7)	15.2 (2.7)	85.5
				TmS		2.5 (0.5)	31.6 (4.9)	18.6 (4.3)	16.1 (4.3)	84.0
Wagdy ^[13]	Egypt	12	Yes	TM	30 (30)	2.5 (0.5)	32.1 (4.0)	17.1 (3.5)	15.0 (3.6)	88.0
				240° trabeculectomy		14.1 (2.3)	28.2 (1.7)	14.0 (1.9)	14.3 (1.8)	93.3 ^d
Rolim-de-Moura <i>et al.</i> ^[14]	Brazil	12	Yes	CTTM	13 (13)	14.2 (3.1)	28.1 (3.5)	13.5 (3.1)	13.5 (3.1)	86.7 ^d
				Baerveldt implant		40.8 (31.7)	22.8 (5.9)	10.6 (6.4)	10.6 (5.2)	100.0
El Sayed <i>et al.</i> ^[15]	Egypt	24	No	CTTM	62 (62)	28.6 (17.7)	23.7 (7.3)	8.6 (8.0)	8.1 (6.7)	100.0
				IMCT		5.6 (4.8)	25.1 (6.4)	13.3 (5.7)	13.2 (5.5)	89.3
Shakrawal <i>et al.</i> ^[16]	India	12	No	CPT	40 (31)	4.4 (3.8)	22.3 (5.2)	7.9 (5.1)	9.5 (4.8)	56.3
				IMCT		6.5 (3.9)	24.7 (3.9)	14.7 (3.5)	15.2 (3.4)	90.0
Khalil <i>et al.</i> ^[17]	Egypt	36	No	CPT	28 (28)	10.2 (5.4)	24.6 (3.3)	12.2 (2.9)	12.9 (2.9)	70.0
				CTTM		6.5 (3.9)	24.1 (1.9)	12.7 (4.2)	14.1 (1.8)	85.7 ^d
Temkar <i>et al.</i> ^[18]	India	12	No	CTTM	60 (30)	5.6 (4.0)	24.1 (1.8)	11.6 (4.5)	13.6 (1.8)	85.7 ^d
				IMCT		6.6 (5.7)	21.8 (9.8)	10.4 (8.9)	10.2 (8.6)	93.3
ElSheikha <i>et al.</i> ^[19]	Egypt	6	Yes	CTTM	41 (31)	6.6 (5.7)	21.7 (8.9)	10.7 (8.0)	10.1 (7.8)	93.3
				CPT + VC		6.8 (6.5)	23.5 (5.4)	6.1 (6.4)	NA	66.7
Bayoumi ^[20]	Egypt	12	No	CPT	20 (20)	6.9 (5.7)	24.3 (4.4)	6.4 (6.4)	NA	60.0
				CTTM		4.7 (2.0)	16.7 (4.3)	10.9 (4.0)	11.8 (3.7)	100 ^b
Reddy <i>et al.</i> ^[21]	India	6	No	CTTM + DS	32 (18)	7.0 (3.8)	16.4 (8.4)	10.9 (7.4)	10.8 (7.3)	100 ^b
				CTTM		< 24.0	24.9 (6.8)	9.0 (5.9)	NA	75.0
Noureddin <i>et al.</i> ^[22]	Lebanon	12	No	TM	16 (8)	< 24.0	27.3 (4.6)	12.3 (5.0)	NA	81.3
				CPT		3.4 (4.1)	34 (2.6)	20.5 (4.2)	18.4 (3.8) ^e	NA
Senft <i>et al.</i> ^[23]	Saudi Arabia	9.5 (2–15) ^c	Yes	VC	20 (10)	3.4 (4.1)	32.3 (4.1)	17.2 (5.8)	19.4 (4.0) ^e	NA
				Goniotomy		5.7 (3.9)	28.4 (4.6)	4.8 (7.8) ^f	NA	40.0 ^b
Anderson ^[24]	USA	34	No	Laser goniotomy	18 (9)	5.7 (3.9)	29.5 (11.0)	6.4 (10.1) ^f	NA	40.0 ^b
				Goniotomy		< 9.0	NA	NA ^g	NA	66.6 ^b
				CPT		< 9.0	NA	NA ^g	NA	66.6 ^b

Data on age, IOP, and surgical success rate were rounded to one decimal place, if applicable.

CPT, conventional partial trabeculectomy; CTTM, combined trabeculectomy-trabeculectomy with mitomycin C; DS, deep sclerectomy; IMCT, illuminated microcatheter-assisted circumferential trabeculectomy; IOP, intraocular pressure; KDB, Kahook dual blade; NA, not available; TM, trabeculectomy with mitomycin C; TmS, trabeculectomy with modified scleral bed; VC, viscocanalostomy; VCST, visco-circumferential-suture-trabeculectomy.

^aAdopted data for the closest point in time to postoperative 6 months in cases where their data are not available.

^bNo distinction between complete (absolute) and qualified success.

^cAverage follow-up duration (range).

^dComplete (absolute) surgical success rate.

^eAdopted postoperative 16-month IOP data due to lack of 1-year data.

^fAdopted IOP data following surgical intervention (measurement period not specified).

^gAdopted average IOP value for all of the other included CPT studies' postoperative 6-month data due to lack of data (applied identical values for both interventions, considering their identical surgical success rates).

We assessed NMA-estimate confidence by a semiautomated web application [Confidence in Network Meta-analysis (CINeMA); Institute of Social and Preventive Medicine]^[40,41]. A comparison-adjusted funnel plot with an accompanying Egger’s test for asymmetry was used to assess cross-study bias (i.e. publication bias) in NMA^[42]. Statistical significance was recorded for cases where the two-sided α level was less than 0.05.

For the purposes of a sensitivity analysis, we repeated an NMA (1) for the primary outcome by excluding studies that had included patients with a history of previous surgery and (2) for the mean IOP reduction at 1-year postoperatively.

Results

Search results

Our systematic search uncovered 1186 articles, of which 1162 were unique reports; after excluding reports based on scrutiny of titles and abstracts, 58 full-text articles were retrieved. Upon full evaluation of these citations, 16 RCTs, comprising a total of 710 eyes from 485 participants, were deemed to have met the NMA

inclusion criteria. Figure 1 is a flowchart of the process of selection for inclusion in our study. The excluded studies along with the rationales for their exclusion are provided in Supplementary Appendix 2, Supplemental Digital Content 4, <http://links.lww.com/JS9/A166>.

Study characteristics

The characteristics of the 16 RCTs included in the NMAs are provided in Table 2. Study duration (i.e. follow-up duration) ranged from 6 to 60 months, and the baseline mean IOP ranged from 16.4 to 34.0 mmHg. Nine studies had been conducted in Egypt^[9–13,15,17,19,20], three in India^[16,18,21], and one each in Brazil^[14], Lebanon^[22], Saudi Arabia^[23], and the USA^[24]. Twelve studies^[9–12,15–18,20–22,24] included only patients lacking any surgical history, whereas four^[13,14,19,23] also included such patients. A schematic of the ROB assessment across all of the studies included in our analysis is provided in Supplementary Appendix 3, Supplemental Digital Content 4, <http://links.lww.com/JS9/A166>. Overall, the trials were determined to have a low-to-moderate ROB.




Figure 1. Flow diagram of study selection process for inclusion in network meta-analysis.

Primary outcome: intraocular pressure reduction

The total of 13 surgical interventions formed a 14-node network of both single interventions and intervention combinations (Fig. 2). As shown in Fig. 3A, IMCT effected a greater IOP reduction than did CPT, when combined in the NMA (MD: -3.10; 95% CI: -5.50 to -0.69, *P*-score=0.752; Supplementary Appendix 4, Supplemental Digital Content 4, <http://links.lww.com/JS9/A166>). However, the amounts of IOP reduction of the other 10 single surgical interventions and those of the two surgical intervention combinations were not significantly different from that of CPT, wherein TmS showed the lowest MD, followed by TM, Baerveldt implant, Laser goniotomy, 240° trabeculotomy, CTTM+DS, CTTM, KDB trabeculectomy, Goniotomy, CPT+VC, VCST, and VC (Fig. 3A). For illustration of the head-to-head comparisons, a net league table is provided in the form of Supplementary Figure 1A, Supplemental Digital Content 4, <http://links.lww.com/JS9/A166>.

Secondary outcome: surgical success rate

Fifteen studies^[9–21,23,24] had reported success rates, entailing 13 intervention nodes (Supplementary Fig. 2, Supplemental Digital Content 4, <http://links.lww.com/JS9/A166>). Complete (absolute) success rates were used in two studies^[13,17] in which qualified success rate data were not available. Also, four studies^[10,20,23,24] reported success rates without any distinction between complete (absolute) and qualified success. Of the present comparison’s interventions, IMCT showed a sig-




Figure 2. Network plot of primary outcome. Surgical interventions, with direct comparisons, are linked by lines, with the width of the lines being proportional to the number of trials comparing each pair of interventions. The size of each node is proportional to the number of eyes of participants (i.e. sample size) randomly assigned to each intervention. Green lines indicate direct comparisons with conventional partial trabeculectomy (CPT); blue indicates direct comparisons with combined trabeculectomy-trabeculectomy with mitomycin C (CTTM); gray indicates direct comparisons between other interventions. DS, deep sclerectomy; IMCT, illuminated microcatheter-assisted circumferential trabeculectomy; KDB, Kahook dual blade; TM, trabeculectomy with mitomycin C; TmS, trabeculectomy with modified scleral bed; VC, viscocanalostomy; VCST, visco-circumferential-suture-trabeculectomy.





Figure 3. Forest plots of primary and secondary outcomes. (A) Mean intraocular pressure (IOP) reduction at postoperative 6 months. (B) Surgical success rate. Each surgical intervention was compared with conventional partial trabeculectomy (CPT), which was the reference group. CTTM, combined trabeculectomy-trabeculectomy with mitomycin C; DS, deep sclerectomy; IMCT, illuminated microcatheter-assisted circumferential trabeculectomy; KDB, Kahook dual blade; MD, mean difference; OR, odds ratio; TM, trabeculectomy with mitomycin C; TmS, trabeculectomy with modified scleral bed; VC, viscocanalostomy; VCST, visco-circumferential-suture-trabeculectomy.

nificantly higher success rate than that for CPT when combined in the NMA (OR: 4.38; 95% CI: 1.61–11.96; Fig. 3B). However, comparisons of others’ success rates with that of CPT were not statistically significant, with ORs ranging from 1.42 (CPT+VC) to 3.47 (VCST) (Fig. 3B). A net league table representative of the head-to-head comparison is shown in Supplementary Figure 1B, Supplemental Digital Content 4, <http://links.lww.com/JS9/A166>. According to the *P*-scores, IMCT (*P*-score =0.777) was the most efficacious surgical intervention as well (Supplementary Appendix 4, Supplemental Digital Content 4, <http://links.lww.com/JS9/A166>).

Examination of network model and validity of results

Our network model revealed moderate heterogeneity across studies for primary outcome ($I^2 = 50.6\%$). Within-design heterogeneity was not significant ($P = 0.208$), though between-design inconsistency was borderline-significant ($P = 0.087$). When a full design-by-treatment random-effects model was assumed, the Q value was low ($Q = 2.41$), and the between-design inconsistency ceased to be significant ($P = 0.120$; Supplementary Table 3, Supplemental Digital Content 4, <http://links.lww.com/JS9/A166>). The SIDE analysis showed no disagreement (inconsistency) between the direct estimates and the indirect ones (all $P_s \geq 0.05$; Supplementary Table 4, Supplemental Digital Content 4, <http://links.lww.com/JS9/A166>). The comparison-adjusted funnel plot, which evaluated the risk of publication bias incurred in the NMA (Supplementary Fig. 3, Supplemental Digital Content 4, <http://links.lww.com/JS9/A166>), showed a relatively even distribution, which is to say, no bias to either side. This was corroborated by the Egger's test, which indicated no significance ($P = 0.34$). These findings,

overall, indicated a low probability of small-study effects in the present network model. As for the primary outcome (i.e. IOP reduction), we examined the overall evidence certainty within the all-comparison network, and found it to be widely distributed from very low to moderate (Supplementary Appendix 5, Supplemental Digital Content 4, <http://links.lww.com/JS9/A166>).

Sensitivity analyses

In our analysis of mean IOP reduction at postoperative 6 months, which excluded studies that had included patients with a surgery history (Fig. 4A), IMCT showed a greater IOP reduction than did CPT, when combined in the NMA (MD: -3.05 ; 95% CI: -5.99 to -0.12 ; Fig. 4B, P -score = 0.761; Supplementary Appendix 4, Supplemental Digital Content 4, <http://links.lww.com/JS9/A166>). The amounts of mean IOP reduction of the others, however, were not significantly different from that of CPT, with MDs ranging from -5.60 (TmS) to -0.25 (KDB trabeculectomy) (Fig. 4B). For illustration of head-to-head comparisons, a net




Figure 4. Network plots and forest plots for sensitivity analyses. (A and B) Mean intraocular pressure (IOP) reduction at postoperative 6 months, excluding studies that had included patients with history of previous surgery. (C and D) Mean IOP reduction at postoperative 1 year. In the forest plots, each surgical intervention was compared with conventional partial trabeculectomy (CPT), which was the reference group. CTTM, combined trabeculectomy-trabeculectomy with mitomycin C; DS, deep sclerectomy; IMCT, illuminated microcatheter-assisted circumferential trabeculectomy; KDB, Kahook dual blade; MD, mean difference; TM, trabeculectomy with mitomycin C; TmS, trabeculectomy with modified scleral bed; VC, viscocanalostomy; VCST, visco-circumferential-suture-trabeculectomy.

league table is provided in the form of Supplementary Figure 4A, Supplemental Digital Content 4, <http://links.lww.com/JS9/A166>.

A total of 12 studies^[9–18,20,22] with nine intervention nodes were included in our analysis of mean IOP reduction at postoperative 1 year (Fig. 4C). The IMCT effected a greater IOP reduction than did CPT (MD: -2.43 ; 95% CI: -4.15 to -0.72), while the others showed no significant differences with that of CPT, with MDs ranging from -2.44 (Baerveldt implant) to -0.74 (240° trabeculotomy) (Fig. 4D). A net league table is provided in the form of Supplementary Figure 4B, Supplemental Digital Content 4, <http://links.lww.com/JS9/A166>. According to the *P*-scores, IMCT (*P*-score = 0.864) was the most efficacious intervention (Supplementary Appendix 4, Supplemental Digital Content 4, <http://links.lww.com/JS9/A166>).

Discussion

This NMA, including 16 RCTs, represents a comprehensive synthesis of data on the comparative efficacies of different types of surgical interventions for PCG. We found that for pediatric patients with PCG, IMCT is more effective than CPT and that it might be the most efficacious among the total of 13 surgical interventions in terms of both IOP reduction and surgical success rate.

In a traditional pairwise meta-analysis of surgical interventions for PCG, Gagrani et al.^[25] likewise showed that mean IOP may be lower with IMCT than with CPT at 6 and 12 months. The evidence on the comparative efficacies of the other surgical interventions, however, was limited due to either a complete lack of studies or an insufficient number. A total of only seven studies, comprising three different pairwise comparisons, were included in their analysis, since the comparisons were limited to specific, direct-evidence-based ones. Going beyond this limitation, our NMA enabled both direct and indirect comparisons between interventions, exploiting all available evidence across the network while preserving within-trial randomization.

The results of our NMA revealed that IMCT is more efficacious than CPT in both IOP reduction and surgical success rate, though the reasons have yet to be elucidated. There are two possible explanations. First, a greater extent of angle opening in IMCT than in CPT could lead to a larger amount of aqueous drainage, resulting in greater IOP reduction and a correspondingly higher surgical success rate. Whereas CPT opens the angle partially, usually 100 – 120° , IMCT effects 360° of circumferential angle opening^[8]. Second, during IMCT, the illuminated microcatheter tip is continuously visible transsclerally throughout the Schlemm's canal passage. The visibility of the tip might minimize the risk of misdirection and false passage^[43], thereby contributing to better surgical outcomes.

In the built-up hierarchies of the interventions, IMCT was identified as the most efficacious surgical intervention with regard to surgical success rate, as it was in the sensitivity analyses on mean IOP reduction at 1-year postoperatively. In most of the head-to-head comparisons between IMCT and the others (other than CPT), however, the differences did not reach statistical significance. Therefore, given the evidence gathered to date, the superiority of IMCT over other interventions (other than CPT) is not yet clear and needs further investigation.

Several study limitations merit further discussion. First, the relatively small sample size in each trial might have incurred a

small-study effect, which refers to the phenomenon that smaller trials show different, often larger treatment effects than larger ones^[44]. The wide CI in studies with small sample sizes also should be taken into account when interpreting the results. Second, subgroup analyses by characteristics such as ethnicity, geographic location, disease severity, or age of onset were not feasible due to the inaccessibility of individual patient data or an insufficient number of trials. It has been reported that PCG incidence varies greatly with race, ethnicity, and level of consanguinity in the community^[45]. Moreover, the prognosis of children with PCG has been known to differ according to age of onset^[46,47]. Further studies examining other confounding factors are required in order to fully evaluate the comparative efficacies of surgical interventions for PCG. Third, the cross-trial definitions of surgical success rate and follow-up period were inconsistent, and these differences might limit the interstudy comparability. We had attempted to perform subgroup analyses according to the surgical success criteria. However, the number of studies in each subgroup included was relatively small for meaningful analyses. Outcome measures for future research should be standardized so as to improve the comparability of studies. Fourth and finally, studies investigating the effect of adjunct usage itself (e.g. IOP-lowering effect of 'TLE with MMC' vs. 'TLE without MMC') in surgical intervention could not be included in the final analysis because their study design or participants were not compliant with the current study's eligibility criteria.

Notwithstanding these limitations, our study is of value, especially in light of the difficulties inherent in performing RCTs on PCG (due to its rarity), the reported incidence of which is known to range from 1 : 10 000 to 1 : 20 000 live births^[45,48–50] and to be higher in consanguineous populations (1 : 1250 in Slovakian gypsies^[50], 1 : 2500 in Saudi Arabia^[51], and 1 : 3300 in Andhra Pradesh, India^[52]). Currently, among practitioners, there is no consensus on the surgical approach to PCG, which uncertainty may hinder their decision making and performance with respect to the optimal treatment modality for each patient. We believe that our NMA could form the basis for the establishment of evidence-based guidelines for the management of PCG.

The findings of the current study indicate several directions for future research. First, larger, multiethnic, and multicountry RCTs with long-term follow-ups are required to further accumulate evidence on the efficacy of surgical interventions for PCG. Second, utilization of a standardized reporting system for surgical outcomes is needed to improve comparability between studies. Third, studies comparing the complications of surgical interventions would also provide valuable information for practitioners on patient management, particularly regarding safety issues. Fourth and finally, investigations gathering evidence on the cost-effectiveness of surgical interventions or the quality of life of patients or caregivers would be worthwhile.

Conclusions

This NMA of RCTs indicated that IMCT is more effective than CPT and, moreover, that it might be the most efficacious of the 13 surgical interventions for PCG. These findings would provide comprehensive evidence for the determination of optimal treatment strategies for PCG in clinical practice.

Ethical approval

Not applicable.

Sources of funding

This study was supported by a National Research Foundation of Korea (NRF) grant (no. NRF-2022R1F1A1064186). The funder had no role in the initiation or design of the study, collection of samples, analysis, interpretation of data, paper writing, or submission for publication. The study and researchers are independent of the funder.

Author contribution

Y.K.K.: concept and design, and obtained funding. Y.J.L.: drafting of the manuscript. Y.J.L., A.H., Y.K.K.: critical revision of the manuscript for important intellectual content. S.R.S., Y.K.K.: statistical analysis. A.H., Y.K.K.: administrative, technical, or material support and supervision. Acquisition, analysis, or interpretation of data done by all authors.

Conflicts of interest disclosure

None declared.

Research registration unique identifying number (UIN)

1. Name of the registry: PROSPERO.
2. Unique identifying number or registration ID: CRD42022313954.
3. Hyperlink to your specific registration (must be publicly accessible and will be checked): https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022313954.

Guarantor

Young Kook Kim and Ahnul Ha.

Data statement

All data generated or analyzed during this study are included in this article.

Provenance and peer review

Not commissioned, externally peer-reviewed.

References

- [1] Stamper RL, Lieberman MF, Drake MV. Developmental and childhood glaucoma. In: Stamper RL, Lieberman MF, Drake MV, editors. *Becker-Shaffer's Diagnosis and Therapy of the Glaucomas*, 8th ed. Mosby Elsevier; 2009:pp. 294–329.
- [2] Franks W, Taylor D. Congenital glaucoma — a preventable cause of blindness. *Arch Dis Child* 1989;64:649–50.
- [3] Gilbert CE, Canovas R, Kocksch de Canovas R, *et al.* Causes of blindness and severe visual impairment in children in Chile. *Dev Med Child Neurol* 1994;36:326–33.
- [4] Haddad MA, Sei M, Sampaio MW, *et al.* Causes of visual impairment in children: a study of 3,210 cases. *J Pediatr Ophthalmol Strabismus* 2007;44:232–40.

- [5] Sitorus RS, Abidin MS, Prihartono J. Causes and temporal trends of childhood blindness in Indonesia: study at schools for the blind in Java. *Br J Ophthalmol* 2007;91:1109–13.
- [6] Dorairaj SK, Bandrakalli P, Shetty C, *et al.* Childhood blindness in a rural population of southern India: prevalence and etiology. *Ophthalmic Epidemiol* 2008;15:176–82.
- [7] Shields MB, Allingham RR, Damji KF, *et al.* Congenital glaucoma. In: Allingham RR, Damji KF, Freedman S, Moroi SE, Shafranov G, editors. *Shields' Textbook of Glaucoma*, 5th ed. Lippincott Williams & Wilkins; 2005:pp. 235–252.
- [8] Shields MB, Allingham RR, Damji KF, *et al.* Medical and surgical treatment for childhood glaucomas. In: Allingham RR, Damji KF, Freedman S, Moroi SE, Shafranov G, editors. *Shields' Textbook of Glaucoma*, 5th ed. Lippincott Williams & Wilkins; 2005:pp. 623–643.
- [9] Elwehidy AS, Bayoumi NHL, Abd Elfattah D, *et al.* Surgical outcomes of visco-circumferential-suture-trabeculotomy versus rigid probe trabeculotomy in primary congenital glaucoma: a 3-year randomized controlled study. *J Glaucoma* 2022;31:48–53.
- [10] Elhilali HM, El Sayed YM, Elhusseiny AM, *et al.* Kahook dual blade ab-interno trabeculotomy compared with conventional goniotomy in the treatment of primary congenital glaucoma: 1-year results. *J Glaucoma* 2021;30:526–31.
- [11] Elwehidy AS, Hagraas SM, Bayoumi N, *et al.* Five-year results of visco-trabeculotomy versus conventional trabeculotomy in primary congenital glaucoma: a randomized controlled study. *Eur J Ophthalmol* 2021;31:786–95.
- [12] Bor'i A, Al-Mosallamy SM, Elsayed TG, *et al.* C-sparing novel technique for subcleral trabeculotomy in primary congenital glaucoma. *J Ophthalmol* 2020;2020:2017158.
- [13] Wagdy FM. Ab externo 240-degree trabeculotomy versus trabeculotomy-trabeculotomy in primary congenital glaucoma. *Int Ophthalmol* 2020;40:2699–706.
- [14] Rolim-de-Moura C, Esporcatte BLB, Netto CF, *et al.* Baerveldt implant versus trabeculectomy as the first filtering surgery for uncontrolled primary congenital glaucoma: a randomized clinical trial. *Arq Bras Oftalmol* 2020;83:215–24.
- [15] El Sayed Y, Gawdat G. Two-year results of microcatheter-assisted trabeculotomy in paediatric glaucoma: a randomized controlled study. *Acta Ophthalmol* 2017;95:e713–9.
- [16] Shakrawal J, Bali S, Sidhu T, *et al.* Randomized trial on illuminated-microcatheter circumferential trabeculotomy versus conventional trabeculotomy in congenital glaucoma. *Am J Ophthalmol* 2017;180:158–64.
- [17] Khalil DH, Abdelhakim MA. Primary trabeculotomy compared to combined trabeculectomy-trabeculotomy in congenital glaucoma: 3-year study. *Acta Ophthalmol* 2016;94:e550–4.
- [18] Temkar S, Gupta S, Sihota R, *et al.* Illuminated microcatheter circumferential trabeculotomy versus combined trabeculotomy-trabeculectomy for primary congenital glaucoma: a randomized controlled trial. *Am J Ophthalmol* 2015;159:490–7.
- [19] ElSheikha OZ, Abdelhakim MASE, Elhilali HM, *et al.* Is visco-trabeculotomy superior to conventional trabeculotomy in the management of Egyptian infants with congenital glaucoma? *Acta Ophthalmol* 2015;93:e366–71.
- [20] Bayoumi NH. Deep sclerectomy in pediatric glaucoma filtering surgery. *Eye (Lond)* 2012;26:1548–53.
- [21] Reddy B, Dada T, Sihota R, *et al.* Comparative evaluation of trabeculotomy-trabeculectomy with mitomycin c versus trabeculectomy with mitomycin C for primary congenital glaucoma. *J Curr Glaucoma Pract* 2011;5:15–9.
- [22] Nouredin BN, El-Haibi CP, Cheikha A, *et al.* Viscoanalostomy versus trabeculotomy ab externo in primary congenital glaucoma: 1-year follow-up of a prospective controlled pilot study. *Br J Ophthalmol* 2006;90:1281–5.
- [23] Senft SH, Tomey KF, Traverso CE. Neodymium-YAG laser goniotomy vs surgical goniotomy. A preliminary study in paired eyes. *Arch Ophthalmol* 1989;107:1773–6.
- [24] Anderson DR. Discussion of paper by Quigley HA. *Ophthalmology* 1982;89:226–56.
- [25] Gagrani M, Garg I, Ghate D. Surgical interventions for primary congenital glaucoma. *Cochrane Database Syst Rev* 2020;8:CD008213.
- [26] Lumley T. Network meta-analysis for indirect treatment comparisons. *Stat Med* 2002;21:2313–24.
- [27] Salanti G, Ades A, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. *J Clin Epidemiol* 2011;64:163–71.

- [28] Lee YJ, Kang D, Lee JE, *et al.* Protocol for systematic review and network meta-analysis of comparative effectiveness of surgical interventions for primary congenital glaucoma. *BMJ Open* 2022;12:e064264.
- [29] Page MJ, McKenzie JE, Bossuyt PM, *et al.* The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *Int J Surg* 2021;88:105906.
- [30] Shea BJ, Reeves BC, Wells G, *et al.* AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. *BMJ* 2017;358:j4008.
- [31] Rucker G. Network meta-analysis, electrical networks and graph theory. *Res Synth Methods* 2012;3:312–24.
- [32] Shim SR, Kim S-J, Lee J, *et al.* Network meta-analysis: application and practice using R software. *Epidemiol Health* 2019;41:e2019013.
- [33] Rucker G, Schwarzer G, Krahn U, *et al.* Package ‘netmeta’. *Network Meta-Analysis using Frequentist Methods*. R package version (Version 08-0), 2015.
- [34] Borenstein M, Hedges LV, Higgins JP, *et al.* *Introduction to Meta-Analysis*. John Wiley & Sons; 2021.
- [35] Rucker G, Schwarzer G. Ranking treatments in frequentist network meta-analysis works without resampling methods. *BMC Med Res Methodol* 2015;15:58.
- [36] Higgins JP, Thompson SG, Deeks JJ, *et al.* Measuring inconsistency in meta-analyses. *BMJ* 2003;327:557–60.
- [37] Cochran WG. The comparison of percentages in matched samples. *Biometrika* 1950;37:256–66.
- [38] Cipriani A, Higgins JP, Geddes JR, *et al.* Conceptual and technical challenges in network meta-analysis. *Ann Intern Med* 2013;159:130–7.
- [39] Dias S, Welton NJ, Caldwell DM, *et al.* Checking consistency in mixed treatment comparison meta-analysis. *Stat Med* 2010;29:932–44.
- [40] Nikolakopoulou A, Higgins JP, Papakonstantinou T, *et al.* CINeMA: an approach for assessing confidence in the results of a network meta-analysis. *PLoS Med* 2020;17:e1003082.
- [41] Papakonstantinou T, Nikolakopoulou A, Higgins JP, *et al.* CINeMA: Software for semiautomated assessment of the confidence in the results of network meta-analysis. *Campbell Syst Rev* 2020;16:e1080.
- [42] Chaimani A, Salanti G. Using network meta-analysis to evaluate the existence of small-study effects in a network of interventions. *Res Synth Methods* 2012;3:161–76.
- [43] Sarkisian SR Jr. An illuminated microcatheter for 360-degree trabeculotomy [corrected] in congenital glaucoma: a retrospective case series. *J AAPOS* 2010;14:412–6.
- [44] Sterne JA, Gavaghan D, Egger M. Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. *J Clin Epidemiol* 2000;53:1119–29.
- [45] Papadopoulos M, Cable N, Rahi J, *et al.* The British Infantile and Childhood Glaucoma (BIG) Eye Study. *Invest Ophthalmol Vis Sci* 2007;48:4100–6.
- [46] Haas J. Principles and problems of therapy in congenital glaucoma. *Invest Ophthalmol* 1968;7:140–6.
- [47] deLuise VP, Anderson DR. Primary infantile glaucoma (congenital glaucoma). *Surv Ophthalmol* 1983;28:1–19.
- [48] Miller SJ. Genetic aspects of glaucoma. *Trans Ophthalmol Soc U K* 1966;86:425–34.
- [49] Francois J. Congenital glaucoma and its inheritance. *Ophthalmologica* 1980;181:61–73.
- [50] Gencik A, Gencikova A, Ferak V. Population genetical aspects of primary congenital glaucoma. I. Incidence, prevalence, gene frequency, and age of onset. *Hum Genet* 1982;61:193–7.
- [51] Jaafar MS. Care of the infantile glaucoma patient. In: Reinecke RD, editor. *Ophthalmology Annual*. Raven Press; 1988:pp. 15–37.
- [52] Dandona L, Williams JD, Williams BC, *et al.* Population-based assessment of childhood blindness in southern India. *Arch Ophthalmol* 1998;116:545–6.